Non-HLA antibodies worsen the histological phenotype and prognosis of antibody mediated rejection in kidney allografts
Kidney International · 2026
DOI: 10.1016/j.kint.2026.06.031 ↗Kurz gefasst
Fachartikel in der Zeitschrift Kidney International, 2026. Verfasst von Emilie Lebraud und 25 weiteren Autor:innen. Beteiligte Einrichtung: Necker-Enfants Malades Institute, Université Paris Cité, Institut National de la Santé et de la Recherche Médicale U1151, Centre National de la Reche…. Hauptthemen laut MEDLINE: Kidney Transplantation, Graft Rejection, HLA Antigens, Isoantibodies. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Société Francophone de Néphrologie Dialyse et Transplantation.
Abstract (Originalsprache)
INTRODUCTION: Antibody-mediated rejection (AMR) remains a leading cause of kidney allograft failure, with both HLA and non-HLA antibodies implicated in its pathogenesis. The contribution of non-HLA antibodies (non-HLA Abs) to microvascular inflammation (MVI) and graft outcome, particularly in cases lacking donor-specific anti-HLA antibodies (HLA-DSAs), remains incompletely understood. METHODS: We analyzed 571 post-transplant serum samples from 326 patients with histological features of AMR (AMRh) and 164 stable control individuals. Non-HLA Abs were detected using the previously developed Non-HLA Antibody Detection Immunoassay (NHADIA), and associations were examined with histological lesions, AMRh persistence, and graft outcomes. Biopsies were scored according to Banff 2022 criteria, and patients were stratified by HLA-DSA and NHADIA status. External validation was also performed in an independent kidney transplant cohort that included 211 biopsies from 189 patients. RESULTS: NHADIA values were significantly higher in patients with AMRh compared to controls, regardless of HLA-DSA status. NHADIA values correlated with the severity of glomerulitis, peritubular capillaritis and global MVI scores. In patients with AMRh and HLA-DSAs, non-HLA Abs remained independently associated with MVI severity. Follow-up biopsies revealed persistent AMR lesions in patients with both HLA-DSAs and non-HLA Abs. Allograft survival was lowest in double-positive patients, and NHADIA positivity independently and significantly predicted graft loss (hazard ratio 2.25, 95% confidence interval 1.03-4.92). Association of non-HLA Abs with Banff lesions severity and death-censored graft survival was replicated in the external validation cohort. CONCLUSIONS: Post-transplant detection of non-HLA antibodies identifies a distinct subset of AMR with more severe histology and worse graft prognosis, particularly when coexisting with HLA-DSAs. Integrating non-HLA Ab testing into current diagnostic frameworks may refine AMR classification and improve risk stratification.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Necker-Enfants Malades Institute, Université Paris Cité, Institut National de la Santé et de la Recherche Médicale U1151, Centre National de la Recherche Scientifique Unité Mixte de Recherche 8253, Paris, France. Electr…
- Necker-Enfants Malades Institute, Université Paris Cité, Institut National de la Santé et de la Recherche Médicale U1151, Centre National de la Recherche Scientifique Unité Mixte de Recherche 8253, Paris, France; Depart…
- Necker-Enfants Malades Institute, Université Paris Cité, Institut National de la Santé et de la Recherche Médicale U1151, Centre National de la Recherche Scientifique Unité Mixte de Recherche 8253, Paris, France.
- Université Marie et Louis Pasteur, Etablissement Français du Sang Bourgogne-Franche-Comté, Institut National de la Santé et de la Recherche Médicale Unité Mixte de Recherche 1098 Regulation of Immunity for Therapeutic I…
- Department of Microbiology, Immunology and Transplantation, KU Leuven, Leuven, Belgium.
- Department of Nephrology and Kidney Transplantation, Necker Hospital, Assitance Publique - Hôpitaux de Paris, Paris, France.
Förderung
- Société Francophone de Néphrologie Dialyse et Transplantation
Zitieren
APA
Lebraud, E., Aubert, O., Aouni, L., Garcia, V., Morin, L., Eloudzeri, M., Lamarthée, B., Zuber, J., Ramaugé Parra, C., Try, M., Coemans, M., Kuypers, D., Wellekens, K., Debyser, T., Lehnert, P. K., Abderrahmane, A., Taupin, J. L., Jager, C., Holleville, Q., …, & Anglicheau, D. (2026). Non-HLA antibodies worsen the histological phenotype and prognosis of antibody mediated rejection in kidney allografts. Kidney International. https://doi.org/10.1016/j.kint.2026.06.031
Vancouver
Lebraud E, Aubert O, Aouni L, Garcia V, Morin L, Eloudzeri M, et al. Non-HLA antibodies worsen the histological phenotype and prognosis of antibody mediated rejection in kidney allografts. Kidney International. 2026. doi:10.1016/j.kint.2026.06.031
BibTeX
@article{Lebraud2026,
author = {Lebraud, Emilie and Aubert, Olivier and Aouni, Laïla and Garcia, Virginia and Morin, Lise and Eloudzeri, Maëva and Lamarthée, Baptiste and Zuber, Julien and Ramaugé Parra, Corentin and Try, Mélanie and Coemans, Maarten and Kuypers, Dirk and Wellekens, Karolien and Debyser, Tim and Lehnert, Priyanka Koshy and Abderrahmane, Adel and Taupin, Jean-Luc and Jager, Chloé and Holleville, Quentin and Normand, Corinne and Bienaimé, Frank and Garcelon, Nicolas and Terzi, Fabiola and Naesens, Maarten and Rabant, Marion and Anglicheau, Dany},
title = {Non-HLA antibodies worsen the histological phenotype and prognosis of antibody mediated rejection in kidney allografts},
journal = {Kidney International},
year = {2026},
doi = {10.1016/j.kint.2026.06.031}
}
EUVIMED